preto-perola-shutterstock-com-1

Preto Perola / Shutterstock.com

12 November 2015Big PharmaDuncan Ribbons and Maeve Lynch

CRISPR: the shifting sands of patentability

CRISPR/Cas9 (clustered regularly interspaced short palindromic repeat/CRISPR-associated protein 9) technology is a revolutionary method of modifying genomic sequences. Although genomic modification has been possible for many years, CRISPR technology is cheaper, easier and more accurate than the modification tools preceding it.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

G 2/21: how to support inventive steps in patentability

7 April 2022 A new referral to the European Patent Office’s enlarged board of appeal will determine whether post-filed data can be used to support inventive steps in patentability, as Sarah Gibbs of Appleyard Lees reports.

USPTO ignites CRISPR/Cas9 patent battle

13 January 2016 Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.

More on this story

article

G 2/21: how to support inventive steps in patentability

7 April 2022 A new referral to the European Patent Office’s enlarged board of appeal will determine whether post-filed data can be used to support inventive steps in patentability, as Sarah Gibbs of Appleyard Lees reports.

USPTO ignites CRISPR/Cas9 patent battle

13 January 2016 Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.

More on this story

article

G 2/21: how to support inventive steps in patentability

7 April 2022 A new referral to the European Patent Office’s enlarged board of appeal will determine whether post-filed data can be used to support inventive steps in patentability, as Sarah Gibbs of Appleyard Lees reports.

USPTO ignites CRISPR/Cas9 patent battle

13 January 2016 Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.

More features

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

Sandoz lands reduced antitrust award of $70m

Teva faces $500m fine for antitrust breaches over MS drug

Pfizer infringed haemophilia therapy patent, says court

Big Pharma counsel embrace AI but data and legal risks loom

MSN scores win in battle with Novartis over heart drug generic

HR, lobbying and business strategy…all in a day’s work for today’s counsel